Aeterna Zentaris (TSE: AEZ) has suffered a dramatic fall in share price due to disappointing results in a recent Phase III clinical trial.
The Canadian biopharmaceutical group announced top-line results from a confirmatory trial of Macrilen (macimorelin), a synthetic small molecule and ghrelin agonist.
The data showed macimorelin did not achieve equivalence to the insulin tolerance test (ITT) in the diagnosis of growth hormone deficiency in adults (AGHD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze